Deals
By partnering with a UN-backed body, Roche has enabled companies to make the medicine for supply in 129 countries.
FEATURED STORIES
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Gilead, AstraZeneca and Vertex have acquired more than just a therapeutic asset in recent deals. BioSpace takes a look at five recent transactions where the staff was the real centerpiece.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Adding to its list of achievements, on Tuesday the Swiss biotech announced it is acquiring Comet Therapeutics.
The hot days of summer are nearing a close, but these life science companies aren’t cooling off their fundraising efforts. Here’s a brief overview of who’s heating up their coffers this week.
The SPAC craze continues as San Diego-based Revelation Biosciences announced its merger with Petra Acquisition that will result in the company’s listing on the Nasdaq exchange.
The combined company out of the Humacyte SPAC will be called Humacyte and is expected to trade shares of common stock and warrants on the Nasdaq Global Select Market.
Tyra Biosciences aspires to raise a $100 million IPO, according to its S-1 form filed with the U.S. Securities and Exchange commission late last week.
Under the terms of the deal, Pfizer is picking up all outstanding shares of Trillium that it doesn’t already own for $18.50 per share in cash.
Google’s Verily snapped up N.C.-based SignalPath and its clinical trial management system that is expected to support its own clinical trial and evidence-based platform known as Baseline.
The Canadian biotech announced the acquisition of two new pipeline assets that align with its focus on autoimmune and kidney-related disease.
Amidst a chorus of pushback from scientific and health organizations, Philip Morris International’s $1.4 billion offer now has the backing of Vectura Group’s board.